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Summary. Progress in treatment for cancer has enabled 
extension of the disease-free interval, and of the quality 
of life for patients, but there has been very little 
improvement in overall survival rates. The main reason 
for this has been the ineffectiveness of current therapies 
to kill all the cancer cells once they have spread to 
distant sites to form metastatic deposits. One marker 
which has proved to be useful in identifying those 
cancers which have the potential to spread is the lectin 
Helixpomatia agglutinin (HPA). In clinical studies, HPA 
binding to primary tumours in tissue sections has been of 
prognostic value in breast, colon and gastric cancer, 
while no prognostic significance for HPA could be 
detected in tumours of the head and neck. These studies 
hence indicate that HPA is best suited to recognise a 
glycotope on adenocarcinomas. In several studies, HPA 
reactivity is equal or superior to other classical markers 
of metastatic potential. Since HPA is a marker of 
prognosis at the level of individual tumour cells, human 
tumour cell lines were screened for their HPA positivity. 
When transplanted into severe combined immuno- 
deficient (scid) mice, HPA positive human breast and 
colon cancer cells metastasised while HPA negative 
cancer cell lines in general did not. In order to define 
HPA binding glycotopes at the molecular level, isolated 
cell membrane glycoproteins were exposed to labelled 
HPA on nitrocellulose membranes after Western blotting 
procedure. The majority of the isolated cell membrane 
glycoproteins bound HPA indicating that not a single 
HPA binding glycoprotein exists, which is associated 
with the metastatic phenotype. Functional investigations 
using the humanlscid mouse chimeras will aid in the 
identification of those HPA positive glycoproteins which 
are functionally involved in the metastatic cascade. 
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Introduction 
It is alarming to note that there has been no recent 
substantial im~rovemen t  in survival rates amongst 
P 
cancer patients suffering from common forms of cancer 
(Sporn, 1996), despite improvements in the under- 
standing of the molecular basis of cancer (Bailar and 
Gornik, 1997). The major reason for this is that there is 
still no effective therapy once the cancer has spread. 
Notwithstanding the increasing armamentarium of 
chemotherapeutic tools at the disposal of the oncologist 
it is not possible to kill what have become known as 
immortalised metastatic cells which are resistant to 
conventional drugs that interfere, for example, with cell 
division. Moreover, mortality rates have remained sadly 
stable in spite of increased detection and prevention 
rates, because of an increasing incidence of cancer. 
The process of metastasis formation is a multistep 
phenomenon, often referred to as the metastatic cascade, 
(Hart et al., 1989; Hart and Saini, 1992), involving the 
loosening of tumour cells from the primary tumour, 
invasion of blood/lymphatic vessels, survival of the cells 
in the circulation, migration out of the vessels, and 
subsequent growth at the distant site. Since all these 
steps have to be carried out sequentially it has proved 
impossible to identify the rate limiting step of metastasis 
formation. 
Carbohydrates and cancer 
Many of the interactions between tumour celllhost 
cell and tumour cell/extracellular matrix described above 
are mediated by carbohydrate residues of the glycocalyx 
of the tumour cell surface, and those of the extracellular 
matrix. These carbohydrate residues of the glyco- 
conjugates are readily identifiable by sugar-binding 
proteins of non-immunological origin which are known 
as lectins. The latter are found widely distributed in 
nature, ranging from plants, invertebrates, and to 
mammals including humans (Lis and Sharon, 1986). The 
word lectin means to choose and was first coined by 
Boyd (1963), though the ability of lectins to agglutinate 
Metastasis, prognosis and HPA 
red blood cells was first reported by Stillmark (1888), 
and is a property relating to the expression of carbo- 
hydrate molecules on the red cell membrane. Indeed, 
some lectins are specific for some human blood groups 
and have, therefore, been widely used in blood group 
typing, whilst others are mitogenic and have, therefore, 
been used as growth stimulators in cell culture systems. 
Lectins have also been used in cancer research because it 
has been shown that some lectins specifically bind to 
particular cancer cells (Aub et al., 1963, 1965; Burger 
and Goldberg, 1967; Burger, 1969). 
The lectin from the Roman snail Helix pomatia 
agglutinin (HPA) has a main carbohydrate specificity for 
N-Acetyl-Galactosamine (GalNAc), and was first 
isolated from the albumin gland of the Roman snail 
Helix pomatia by Hammarstrom and Kabat (1969). It 
was found to be a protein which specifically agglutinated 
human blood group A erythrocytes, of molecular weight 
79 000, and contains about 7% carbohydrate side chains. 
HPA has been shown to bind to cancer cells of some 
tumours which have metastatic potential,  and is 
correlated with the poor survival chances of these 
patients. This article will review the data which have 
been obtained using this lectin in the prediction of 
prognosis in a variety of different cancers (Table 1). 
HPA as a prognostic marker in clinical studies 
HPA and breast cancer 
The ability of HPA to bind to cancer cells was first 
demonstrated in breast cancer by Leathem et al. (1983), 
being further clarified in two subsequent abstracts 
(Leathem et al., 1984, 1985; Leathem and Brooks, 
1987). Leathem and his colleagues used formalin fixed, 
paraffin wax embedded biopsy material from 15 normal 
healthy controls and from 30 patients with breast cancer. 
They found that a panel of lectins including pokeweed 
mitogen (PWM), Lotus tetragonolobus agglutinin (LTA), 
wheatgerm agglutinin (WGA), peanut agglutinin (PNA), 
Helix pomatia agglutinin (HPA), Bandeiraea 
simplicifolia agglutinin I (BSA-I), soy bean agglutinin 
(SBA) and Concanavalin A (Con A) all bound to breast 
cancer cells in a variable, cytoplasmic, luminal surface 
or extracellular pattern. However, they did note that not 
all cancer cells bound the same lectin, suggesting the 
presence of sub-populations with different glycosylation 
pattern within individual tumours. With the exception of 
Con A,  all lectins also bound to normal breast,  
specifically to the apical membrane of the lining 
epithelia1 cells or to the myoepithelial cells, and there 
were some differences in lectin binding between acinar 
and ductal epithelium. The main difference in the 
binding of lectins between normal and malignant cells 
was the transition from a surface to a mainly granular 
cytoplasmic binding pattern. The predominantly luminal 
pattern of lectin binding seen with most of the lectins 
used by Leathem and his colleagues suggested to them 
that there is a concentration of glycoconjugates in 
Table 1. Use of HPA as a prognostic indicator in different cancers in 
clinical studies and animal models. 
CANCER 
Breast carcinoma 
Colorectal 
Oesophageal 
Gastric 
Prostatic 
Bladder 
Lung 
Arneloblastoma 
Melanorna 
Sarcoma 
Colorectal 
Breast 
Ovary 
REFERENCE ANIMAL MODEL 
Leathern et al.. 1983, 1984, 1985 
Leathern and Brooks, 1987 
Brooks and Leathem, 1991 
Fenlon et al., 1987 
Fukutorni et al., 1989 1991 
Thomas et al., 1993 
Alam et al., 1 990 
Brooks et al., 1996 
Noguchi et al., 1993 
lkeda et al., 1994 
Schurnacher et al.. 1994a,b 
Yoshida et al., 1993 
Takahashi et al., 1994 
Kakeji et al., 1991, 1994 
Shirashi et al., 1992 
Langkilde et al., 1989 
Kawai et al., 1991 
Vigneswaran et al., 1993 
Kjonniksen et al., 1994 Nude 
Kjonniksen et al., 1994 Nude 
Schumacher et al., 1994a scid 
Schumacher and Adam 1997 scid 
Schumacher et al., 1996a scid 
normal breast at this particular apical location, and was 
in accord with the demonstration of Franklin (1983), 
although in the latter study a different panel of lectins 
was used. Brooks and Leathem (1991) demonstrated a 
strong association between HPA staining in primary 
breast cancer and the presence of metastases in the local 
draining lymph nodes in a twenty four year retrospective 
study of 373 primary breast cancers (embedded in 
paraffin wax). In life tables calculated for lymph node 
status (metastatic versus non-metastatic) and HPA 
staining versus non-HPA staining patients were almost 
identical over 15 years follow up period. However, there 
was no association with tumour size, histological grade, 
S-phase fraction or age at diagnosis. In summary, it 
appears that whereas normal breast epithelium is 
apically HPA-positive, non-metastatic cancer is HPA- 
negative, and metastasising cancer is HPA-positive all 
over the tumour cell (Leathem et al., 1983). 
Criticisms of the use of HPA as a marker of 
metastatic potential in breast cancer 
There have been critics of the work of Leathem and 
Brooks (1987), and no universal agreement of the value 
of HPA as a prognostic indicator of the metastatic 
potential of human breast cancer exists (Galea et al., 
1991; Taylor et al., 1991; Gusterson et al., 1993). In a 
study of HPA staining of 459 cases of primary breast 
cancers over a six year period, Galea et al. (1991) were 
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unable to reproduce the positive correlation of HPA as a 
predictor of outcome with a higher degree of reliability 
than the established prognostic indicators.  They 
suggested that the differences may be accounted for 
because of the different lectin histochemical methods 
employed, and the source of the lectin itself. Indeed, 
such is the strength of their belief,  despite this 
explanation, that they argued against the use of HPA in 
prognosis prediction, relying on their own negative 
findings and discounting the work of Leathem's group. 
Taylor et al. (1991) also argued against the use of HPA 
as a prognostic tool. In their study based on 363 primary 
breast cancers, these workers also were unable to 
establish a strong correlation between HPA staining and 
metastatic potential as revealed by analysis of lymph 
node involvement. Gusterson et al. (1993) studied 684 
primary breast cancers from the International (Ludwig) 
Breast Cancer Study Group and found only a weak 
correlation between HPA staining and lymph node 
status. They contrasted the large advantage in disease 
free survival and overall survival for node-negative 
patients, with the situation for HPA-negative patients for 
whom there was no such advantage. However, Leathem 
and Brooks replied to their critics Taylor et al. (1991) 
and Galea et al. (1991), commenting that methodological 
differences certainly can account for the different results, 
emphasising that the indirect lectin histochemical 
technique is to be preferred to the direct technique as 
employed by their censors. As pointed out by Walker 
(1993), the level of sensitivity of HPA binding site 
detection seems to be critical in determining the 
prognostic significance. Furthermore, it has been 
demonstrated that methodology (including fixation and 
tissue processing) does indeed make a difference to the 
binding outcome (Brooks et al., 1996). In a twenty four 
year retrospective study on 373 cases of primary breast 
cancers using a direct and an indirect lectin histo- 
chemical technique, Brooks and her colleagues (1996) 
found that there was a considerable difference in the 
lectin binding pattern in individual cases using the two 
different methodologies. This finding is likely to be 
significant since Leathem's group used an indirect 
method whilst the others used a direct lectin histo- 
chemical technique. Indeed, in life table analyses to 
calculate survival-advantage of HPA stainers versus non- 
stainers only the indirect method showed a highly 
significant correlation between HPA binding and 
survival. Hence, it may be difficult to compare the 
results of various studies when different methods of 
tissue preparation and different histochemical techniques 
have been employed. 
Despite the cautionary note many other groups have 
found an association between HPA binding and 
prognosis in breast cancer. In a study of one hundred 
patients presenting during 1977 and 1979, followed up 
over a six year period, Fenlon et al. (1987) evaluated 
HPA binding to human breast carcinomas after trypsin 
pre-digestion of sections, and demonstrated a significant 
correlation of the staining to patient survival. Studies 
showed that the HPA binding related very well to lymph 
node status at the time of resection, and evaluation of the 
follow-up data indicated that patients with primary 
cancers with a greater proportion of cells staining with 
HPA had a shorter survival time. The work of Fukutomi 
et al. (1989) clearly indicated the value of HPA as a 
prognostic indicator: HPA staining was studied in 113 
cases of primary breast cancers, 63 metastatic lymph 
nodes and 10 resected local recurrences demonstrating 
that HPA-positive tumours were associated with a poorer 
5 year survival rate. Fukutomi et al. (1991) followed up 
their earlier work by correlating the prognostic value of 
HPA staining with gene amplifications in human breast 
carcinomas. In particular, the relationships between cell 
surface sugar chains of cancer cells and the amplifi- 
cations of the proto-oncogenes c-myc, int-2, and c-erbB- 
2 were evaluated. It was found that the expression of the 
carbohydrates identified by HPA staining correlated with 
the expression of the proto-oncogene c-myc product. 
The prognostic significance of HPA staining and the 
oncoprotein c-erbB-2 were further evaluated in human 
breast carcinoma by Thomas et al. (1993) in 120 primary 
breast cancers. This group found that tumours which 
were both HPA- and c-erb B-2-positive were highly 
correlated to the presence of axillary lymph node 
metastases, a poorer overall and shorter disease-free 
interval compared to the other indicators considered 
alone. Investigation of the relationship between HPA 
staining and the presence of metastases in the axillary or 
internal mammary lymph nodes was strongly correlated, 
though HPA staining was unable to discriminate between 
the two lymph node groups. Flow cytometric studies of 
cell surface carbohydrates have also been made in 
metastatic breast cancer, including cell aspirates from 
primary adenocarcinoma and from draining lymph nodes 
with metastases (Alam et al., 1990). It was found that 
this technique allowed correlation between HPA staining 
and lymph node involvement in tumours of higher grade 
(I1 and 111), and that the technique could be useful in 
analysis of fine needle aspirates of breast tissue. 
Noguchi et al. (1993) found that evaluation of HPA 
staining combined with DNA ploidy of breast 
carcinomas was a more powerful tool than use of either 
feature alone in the prediction of long term outcome in a 
study of 106 primary breast cancers. This was followed 
up by Leathem's group (Brooks et al., 1993). In this 24 
year retrospective study paraffin wax sections of primary 
breast cancers from 366 patients were evaluated using 
HPA staining, histopathological assessment, and the S- 
phase fraction and ploidy calculated after flow 
cytometry. Data including the tumour size, nodal status 
and age were also recorded. It was found that the 
prognostic significance of altered glycosylation, as 
detected by HPA binding, is unlikely to be through an 
association with proliferative rate, degree of anaplasia, 
or cellular ploidy, but may rather be through a direct 
association with the presence of nodal metastases. 
The ability of metastatic breast cancer cells to bind 
HPA seems to be a relatively constant feature since HPA 
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binding glycoconjugates are expressed in most brain 
metastases (Schumacher et al., 1992), and hence HPA 
may be regarded as a stable marker of metastatic 
potential. Such constancy of lectin binding between 
primary tumours and metastases was not a feature of 
other lectins applied to breast cancer tissues since 
Krogerus and Andersson (1990) did not observe a 
similar constancy of lectin binding site expression using 
a different panel of various lectins including Bandeiraea 
simplicijolia agglutinin I1 (BSA-11), Con A, HPA, PNA, 
Ricinus communis agglutinin (RCA-I or -II), Ulex 
europeaus agglutinin (UEA-I) and WGA. It was found 
that the binding pattern of the primary tumours was 
diverse, whereas in the respective metastases it was 
relatively homogenous. It was concluded that whereas 
there is heterogeneity within the primary tumours, the 
subclones of malignant cells which metastasised had a 
more restricted glycoconjugate expression. This view is 
in accord with the more general observations made by 
Kahn et al. (1988) who examined the lectin binding 
pattern of liver and lung metastasising variants of the 
murine Lewis lung carcinoma. They found that the 
lectin-phenotype of the metastasising cells depended on 
to which organ the cells were seeding. This implied that 
the selective metastasis formation was associated with 
differences in the carbohydrate composition of the 
metastatic tumour cells. 
The  carbohydrate profiles of primary breast 
carcinomas and their metastases has recently been 
investigated by Rye et al. (1993) in 36 primary breast 
cancers and associated axillary lymph nodes. Noting the 
well documented considerable heterogeneity of 
carbohydrate expression in malignant tissues, these 
workers were able to demonstrate almost complete 
homogeneity in carbohydrate expression between 
individual primary breast cancers and their lymph node 
metastases for all the lectins studied (WGA, PNA, LTA, 
HPA and UEA-I). Their findings led them to suggest that 
at this stage of metastasis more subtle changes in 
specific glycoconjugates are responsible for subsequent 
metastatic cell behaviour, rather than widespread 
changes in carbohydrate groups as usually detected by 
lectins. Indeed, Rye et al. (1993) have proposed that 
although the alteration in glycosylation associated with 
malignancy can be identified with lectins, the restricted 
specificity of lectins and the considerable array of 
potential binding sites on and within cells, means that 
any glycosylation differences in sub-populations of 
tumour cells are likely to be too subtle to detect using 
lectin histochemistry. For this reason Rye et al. (1993) 
regarded the use of lectins to be inappropriate and of 
limited prognostic value in breast cancer. However, this 
view is at variance with the earlier studies (vide supra) 
which showed a clear correlation between HPA staining 
and prognosis of breast cancer patients. 
HPA binding and prognosis in other cancers 
In advanced colorectal carcinoma, HPA staining has 
been associated with poor prognosis by Ikeda et al. 
(1994). In the latter work a total of 117 patients were 
studied, with 57 in one group who survived for at least 
five years, and 60 in a second group of patients who 
suffered a recurrence within two years or who died. The 
second group showed a greater intensity of HPA staining 
than the first, and there was a positive correlation in 
multivariate analysis between HPA staining, lymph node 
metastases, and degree of venous invasion. Schumacher 
et al. (1994a) also found significant correlation between 
positive HPA staining of the primary tumour cells and 
prognosis in colorectal carcinoma (n=130) which was 
correlated to the Duke's classification. The presence of 
HPA staining was found to be almost as bad as the 
prognosis for Duke's stage C, as  predicted by 
conventional means. Of the Dukes' C stage patients 73% 
were also HPA-positive. The ability of HPA to 
distinguish between metastasising and non-metastasising 
cancers is quite unique. Using mistletoe lectin I11 (ML- 
111) which has the same nominal monosaccharide 
specificity as HPA, namely GalNAc, Dixon et al. (1994) 
could not find any prognostic value of this lectin in 
colorectal cancer. These findings were elaborated by 
analysing lectin binding sites on isolated membrane 
glycoproteins using Western blotting. ML-I11 bound to 
slightly different membrane glycoproteins as HPA. 
Hence, even subtle differences in the carbohydrate 
composition of glycoconjugates which can be 
differentiated by lectins are of functional significance 
with regard to the metastatic spread of tumours. These 
studies confirmed the earlier histochemical and Western 
blotting studies of LafertC et al. (1995) who reported that 
the combined use of monoclonal antibodies recognising 
blood group A and B oligosaccharides and HPA is able 
to detect glycoproteins specific for colon cancers in rats. 
Poor prognosis has been associated with HPA 
staining in oesophageal carcinoma by Yoshida et al. 
(1993). In their study of 95 patients with primary 
oesophageal carcinoma (tissues collected over a 10 year 
period, 1980-1990) it was possible to relate positive 
HPA staining of the primary tumour to the progression 
of the tumour in terms of its infiltration into the depth of 
the oesophageal wall, and of the degree of venous 
invasion. Similar to other carcinomas the HPA-positive 
patients had a consequently poorer prognosis than those 
who were HPA-negative. These results were confirmed 
by a second publication from Yoshida et al. (1994) who 
studied the number of silver stained nucleolar organizer 
region (NOR) proteins and HPA staining in oesophageal 
carcinomas. They also found that HPA staining 
correlated significantly with increasing depth of the 
carcinoma invasion, venous invasion and tumour stage. 
Of the HPA-negative cases 40142 also had low silver 
stained NORs, whilst 39/52 HPA-positive cases had 
NOR staining. The survival rate of patients with 
advanced carcinoma was significantly poorer for those 
with high NOR staining and HPA-positivity than in 
those with NOR staining and no HPA-reactivity. It was 
concluded that tumours expressing both prognostic 
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indicators represented a subgroup of carcinomas with a 
particularly poor prognosis. In contrast, a down- 
regulation of HPA staining in N-methyl-N7-nitro-N- 
nitrosoguanidine induced oesophageal carcinoma in 
shrews was demonstrated by Takahashi et al. (1994), 
vide infra. 
In gastric carcinoma HPA has been found to be a 
useful prognostic indicator by Kakeji et al. (1991, 1994). 
In this work, HPA staining correlated well with other 
markers of tumour progression i .e.  tumour size, 
penetration, lymphatic invasion, and metastasis. Indeed, 
those patients whose tumours were HPA-positive 
(96/163), and who had carcinoma cells on the serosal 
surface of their stomach, had a lower survival rate. In a 
study of 119 patients with gastric carcinomas, and with 
positive HPA staining (751119) (for whom the 5 year 
survival rate was only 18%) there was also a higher rate 
of abnormal p53 staining (69% of the p53 positive cases 
were also HPA positive), and a higher concentration of 
proliferating cell nuclear antigen staining (38.5% of the 
PCNA positive cases were also HPA positive) (Maehara 
et al., 1995). 
Prostatic carcinomas which had metastasised to bone 
showed a higher incidence of HPA binding than those 
which did not bind the lectin (Shirashi et al., 1992). 
These results indicated that those patients who were 
indigenous Japanese, rather than Japanese Americans or 
whites from Hawaii were more likely to bear tumours 
which were HPA-positive. 
In invasive bladder carcinomas, out of a panel of 
nine lectins, only HPA stained the cancer cells, albeit a 
small percentage (8%) (Langkilde et al., 1989). Indeed, 
the overall finding was that the general decrease in lectin 
staining was accompanied by an increase in the 
progression of urothelial malignancy. This instance of 
down regulation of the glycotopes responsible for HPA 
binding may relate to the changes in the local 
environment, since the down regulation seems specific 
to the urinary bladder location. 
HPA staining has been used to distinguish malignant 
pleural mesothelioma (n=29) from well differentiated 
pulmonary adenocarcinoma (n=38) (Kawai et al., 1991). 
Tissues from these two types of cancer were tested using 
HPA and also an antibody to AJ3H blood group related 
antigens. Reactive mesothelial lesions and malignant 
mesothelioma of the pleura were not stainable with the 
ABH antibody or HPA. However, in pulmonary adeno- 
carcinoma, the ABH antibody reacted with tissues 
expressing the compatible blood group, especially group 
0 .  HPA reacted with adenocarcinomas of blood group 
types A and AB (94% and 100% respectively), with less 
binding to type B (80%) and 0 (33%). It was suggested, 
therefore, that positive reactions with either the ABH 
antibody or HPA can be indicative of well differentiated 
pulmonary adenocarcinoma, and, thus, exclude 
mesothelioma. 
HPA staining has been found to be useful in studying 
human germ cell tumours (Nikawa et al., 1993), though 
in these cases it appears to be a less powerful indicator 
of subsequent prognosis than in the tumours mentioned 
above. In patients with intra-cranial human germ cell 
tumours, in addition to HPA reactivity in neoplastic cells 
irrespective of blood group type, Nikawa et al. (1993) 
found that some vascular endothelial cells and erythro- 
cytes of patients with blood group types A or AB were 
also labelled. HPA-positive neoplastic cells were seen in 
one yolk sac carcinoma in a patient with blood group 
type A, and in embryonal carcinomas and teratomas 
irrespective of blood group type. Although 10118 
germinomas were HPA-negative, 8/18 were HPA- 
positive. Whilst the former showed a very good response 
to radiotherapy, 418 HPA-positive cases showed poor 
radiosensitivity. In this instance the HPA reactivity was 
related to the degree of radiosensitivity of the tumours. 
In 1 8  cases of ameloblastomas, ameloblastic 
carcinomas and basal cell carcinomas Vigneswaran et 
al., (1993) analysed their reaction to HPA. Of the 12 
ameloblastomas 5 were HPA positive. 
HPA is not,  however, a universal marker of 
prognostic relevance since Schumacher et al. (1996) 
found that it bound, to varying extents, to all of a series 
of squamous cell carcinomas of the human aerodigestive 
tract in the head and neck region, and hence was of no 
use as a prognostic indicator (Fig. ID). 
HPA as a predictor of metastatic potential in animal 
models 
It is possible to define the metastatic potential of 
human cancer cells in the clinical studies using HPA. 
This predictive power has been applied to model systems 
as well, which would have clinical relevance with 
respect to carbohydrate expression. In the work by 
Schumacher et al. (1994b) the human colon cancer cell 
line HT29 was injected sub-cutaneously into severe 
combined immunodeficient (scid) mice. Pulmonary 
metastases then rapidly developed in these mice 
spontaneously. Both in vitro and in scid mice the HT29 
cells expressed HPA binding sites, though differences 
were noted (Fig. lA,B). In investigations of the role of 
carbohydrates as revealed by lectin histochemistry in 
animal models of human breast or colon cancers, or in 
cancer cell lines grown in  vitro,  the carbohydrate 
expression associated with metastasis is modulated by 
local environmental differences: HT29 cells grown in 
vitro were more intensively HPA-positive and the 
staining was homogenous as compared to HT29 cells 
grown in vivo in scid mice (Schumacher et al., 1996~) .  
Schumacher and Adam (1997) studied the lectin 
histochemical binding pattern of human breast and colon 
cancers that were associated with metastasis formation 
in scid mice. It was shown, in general, that those cancer 
cell lines which were HPA-positive metastasised, 
whereas those cell lines which were HPA-negative did 
not (Fig. 1C). This work also supported the use of the 
scid mouse model of metastasis formation, as reviewed 
by Mitchell and Schumacher (1997). 
In a study of metastasis formation after intravenous 
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injection of human melanoma and sarcoma cell lines into 
nude mice (Kjonniksen et al. ,  1994), there was a 
relationship between the ability of the carcinoma cells to 
form metastases in the lungs, and HPA staining. 
Pretreatment of the cells with HPA prior to injection, 
however, did not reduce the ability of the cells to 
develop pulmonary metastases, indicating to 
Kjonniksten et al. (1994) that the pulmonary metastatic 
potential was not blocked by HPA, and hence the 
binding partner(s) of HPA was not directly involved in 
the metastatic process. A criticism of this methodology, 
however, is that it is not modelling metastasis formation, 
but simply a seeding via the vascular route. 
A down-regulation of HPA staining in N-methyl- 
N'-nitro-N-nitrosoguanidine induced oesophageal 
carcinoma in shrews was demonstrated by Takahashi et 
al. (1994), as there was for other lectins in the panel 
tested. The reason for the down regulation is not 
clear, but the means of induction of the carcinoma 
may be important in relation to the effect on carbo- 
hydrate expression. Species differences may also be 
important. 
Fig. 1. A. The human colon cancer cell line 
HT29 grown in vitro and stained with HPA. 
Note the intense and homogeneous staining 
of the cells. B. HT29 tumour grown in scid 
mice. This tumour had metastasised to the 
lungs. Note the overall weaker and more 
heterogeneous staining pattern. This 
difference in staining intensity and pattern 
indicates that HPA binding sites are to a 
certain degree subject to cell regulatory 
mechanisms. C. HPA binding to the human 
breast cancer cells MCF-7 grown in a scid 
mouse. Again, a heterogeneity of the 
staining pattern is obvious. The tumour had 
spontaneously metastasised to the lungs. 
D. Human squamous cell carcinoma of the 
oropharynx stained with HPA. Note the 
intense membranous staining pattern. In 
this tumour type, however, HPA binding is 
not associated with metastasis. X 850 
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Identification of possible binding partners of HPA 
HPA binding properties of several human breast 
cancer cell lines have been investigated (Schumacher et 
al., 1995), and it was found that lectin binding was very 
heterogenous between and within the different cell lines 
(and was influenced by the tissue fixation and 
processing). However, some of the cell lines showed 
HPA-binding sites both in sections and in isolated cell 
membrane glycoproteins using Western blots. The latter 
indicated that HPA can bind to several membrane 
glycoproteins. The binding pattern of HPA to most if not 
all membrane glycoproteins in breast cancer cells is of 
significance for the understanding of the glycosylation 
mechanisms in metastasising breast cancer. It should be 
borne in mind that HPA binds to the apical membrane of 
the normal breast epithelium only. The ability to bind 
HPA at all is lost in non-metastasising breast cancer, 
whilst metastasising breast cancer shows HPA binding 
sites on both apical and basolateral membranes. In 
addition, HPA binding sites are located in the cytoplasm 
of the latter tumour cells as well.  To study this 
glycosylation pattern milk fat globule membrane 
glycoproteins were analysed. The milk fat globule 
membrane is a derivative of the apical membrane of the 
normal lactating breast epithelium. By analysing the 
HPA binding sites of these membrane proteins, only two 
to six membrane glycoproteins were detected, which 
bound HPA (Schumacher, 1990). Because almost all 
proteins of breast cancer cells bound HPA, it can be 
assumed that the apical-basolateral divide of HPA 
binding sites broke down in metastatic breast cancer 
cells indicating a switch in glycosylation. 
Ultrastructural analysis of HPA binding sites of 
human breast cancer cell lines showed that after use of a 
pre-embedding technique HPA was bound to the typical 
submembranous granules and surface microvilli, the 
former representing sites of the milk fat globules 
(Mitchell et al., 1995). As to the molecular structure of 
the HPA binding sites, Brooks and Leathem (1995) have 
recently hypothesised that a putative binding partner of 
HPA was the Tn epitope, or the blood group A antigen, 
because in both cases there is an expression of glyco- 
proteins terminating in a-GalNAc. This hypothesis was 
analysed using two monoclonal antibodies, one to Tn 
and another one to a-GalNAc and HPA as well. Only 
small proportions reacted for Tn or a-GalNAC, whereas 
85% were HPA-positive. Indeed, the staining patterns 
indicated that the populations of cells demonstrated were 
different, and this was confirmed in Western blots. Thus, 
it was concluded that breast cancers may express 
complex carbohydrate profiles, but that distinct glycans 
sharing similar terminal GalNAc groups may be 
implicated in the development of the metastatic potential 
of breast cancer. Indeed, Ito et al. (1996) used a panel of 
lectins all binding to glycoconjugates with GalNAc 
residues in their backbone structures, and demonstrated 
that all the lectins bound to the same human breast 
carcinoma cells, and that all carried linear and branched 
poly-N-acetyl-lactosamine on N-glycans, suggesting that 
the synthesis of this complex carbohydrate is one of the 
most important and basic processes leading to the 
malignant transformation of cells,  invasion, and 
metastasis of carcinoma cells. Another potential binding 
partner of HPA may be glycosaminoglycans. However, 
of all the glycosaminoglycans only hyaluronic acid 
has the potential of being a putative binding partner of 
HPA. Hyaluronic acid contains N-Acetyl-glucosamine 
residues, a carbohydrate for which HPA has a minor 
specificity. However, Schumacher et al. (1996b) have 
demonstrated that hyaluronic acid, at least, is not, in 
practice, the binding partner for HPA in breast and colon 
cancer. Hyaluronate digestion of tissue samples from 
human clinical and experimental tumours grown in scid 
mice showed that HPA bound to the tumour cells even 
after hyaluronidase treatment although HPA bound to 
hyaluronic acid in dot blots. Thus, it was suggested that 
the binding partner for HPA was more likely to be a 
GalNAc-containing glycoprotein. 
The binding of HPA to tumour cells is subject to 
regulatory mechanisms. In general, HPA binding sites 
are more homogenous and intensive in breast and colon 
cancer cells grown in vitro, as compared to in vivo (vide 
supra). This variation of carbohydrate binding sites, 
however, is not unique to HPA but can also be found 
using the same cell lines with other lectins having 
different carbohydrate specificities (Schumacher et al. 
1 9 9 6 ~ ) .  These findings accord with the results of the 
work by Berezovskaya et al. (1995) at least for glioma 
cells maintained in vitro. The interaction of the cancer 
cell with its environment is mediated by cell membrane 
glycoprotein receptors. In the glioma cell lines it was 
shown that the increase in the degree of sialylation or 
branching of fucose-containing residues could influence 
cell  adhesion properties, thus creating metastatic 
potential. Indeed, the degree of sialylation of the sub- 
terminal galactose or GalNAc residues shows a good 
correlation with metastatic potential (Altevogt et al., 
1983; Yogeeswaran and Salk, 1991) amongst various 
murine metastatic tumour cell lines. 
HPA staining correlated to other lectin markers of 
metastatic potential in clinical studies 
Another lectin which has been associated with 
metastatic potential in carcinomas, and hence a poor 
prognosis, is Phaseolus vulgaris leucoagglutinin (PHA- 
L). It binds to a different group of carbohydrate residues, 
namely (31-6 branched oligosaccharides. The malignant 
transformation has been associated with the acquisition 
of larger asparagine (N)-linked oligosaccharides (Warren 
et al., 1978), and GlcNAcB(1-6)Mana(l-6)ManB 1-6 
branching asparagine-linked oligosaccharides in human 
breast and colon carcinomas (Fernandes et al., 1991). 
Fernandes et al. (1991) have found a correlation between 
prognosis and PHA-L binding to primary human breast 
and colon cancers. Indeed, Dennis and LafertC (1989) 
had earlier demonstrated that PHA-L bound most 
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strongly to malignant rather than benign breast tissues. 
Recently, Mitchell et al. (1998) compared the binding 
pattern of HPA and PHA-L in parallel sections of a 
series of experimental colon and breast cancers grown in 
SCID mice, as well as in clinical material from patients 
with breast cancer. The histochemical reactions obtained 
with the two lectins resulted in very different staining 
patterns. Indeed, it was shown that HPA was more often 
associated with metastases than PHA-L. The results 
indicated that a common complex type glycoprotein 
terminating with a GalNAc residue is, therefore, unlikely 
to be the binding partner for both lectins. 
Conclusions 
It is clear, despite some contrary views, that HPA 
has some relation to the survival of patients in a variety 
of cancers mostly of the adenocarcinoma type. The 
binding partner of HPA is unknown, though it appears to 
contain a-GalNAc or GlucNAc residues in a glyco- 
protein. The expression of HPA appears to correlate with 
a number of parameters including metastasis formation, 
and the expression of certain oncogene products. In 
multivariate analysis, it is better correlated with patient 
prognosis than with tumour size or differentiation. The 
expression of HPA depends on the techniques used for 
its demonstration, and on whether cancer cells are 
examined in situ or after in vitro culture. Future studies 
of patient prognosis should be aimed at elucidating the 
role of the carbohydrate binding partner of HPA, and its 
role in the metastatic process. Recent progress in 
molecular biology may direct the way in which an 
analysis of HPA binding sites may be fruitful. In 
comparing the gene expression of at least 45000 
different genes from normal colonic mucosa and colon 
carcinoma Zhang et al. (1997) found remarkably few 
differences between the two samples. One gene, whose 
expression was downregulated, however, was a sialyl- 
transferase. If it can be shown that HPA detects a sub- 
terminal carbohydrate residue in metastasising colon 
cancer cells, which is normally masked by sialic acid, a 
remarkable step forward in the understanding of the 
metastatic cascade will have been made. Current work in 
our laboratory is now focusing on this promising path to 
elucidate the role of this sialyltransferase activity to 
mask HPA binding sites in non-metastasising cancers. 
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